Nilotinib Hydrochloride (TKI) plays a vital role in chronic myelogenous leukemia (CML) treatment. However, its production can be complex and impact the environment. Fortunately, research is driving the development of more efficient and sustainable methods for manufacturing Nilotinib Hydrochloride API (Active Pharmaceutical Ingredient). https://www.qingmupharm.com/pr....oducts/human-apis/ni